Navigation Links
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
Date:8/22/2007

- Revised Trial Examines Single, Higher, More Concentrated Dose of

Alfimeprase -

SAN CARLOS, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced enrollment of the first patient in the SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-3) trial evaluating lead product candidate, alfimeprase, for the treatment of central venous catheter occlusion (CO).

This open-label, single-arm trial will evaluate the safety and efficacy of a single 10 milligram dose of alfimeprase with a concentration of 5 milligrams per milliliter in up to 100 patients with occluded central venous catheters.

Data from a previous Phase 3 trial in the CO program, SONOMA-2, showed that alfimeprase restored catheter function in patients with occluded catheters within 15 minutes with a p-value of 0.022. It did not however, meet the more stringent p-value required for a single pivotal trial, less than 0.00125.

"Analysis of data from our previous Phase 3 SONOMA study provided further evidence that alfimeprase is an active thrombolytic which has the potential to dissolve clots quickly and rapidly restore catheter function, however, the dose and concentration we used did not generate results in line with the target product profile we believe necessary for commercial success in this market," said Michael Levy, M.D., executive vice president of research and development for Nuvelo. "Preclinical experiments have provided evidence that increasing the concentration can result in marked improvement in thrombolytic activity. Accordingly, we are resuming development of alfimeprase in CO to evaluate the potential of a single, higher, m
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
6. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014  Advanced Medical Isotope ... company engaged primarily in the development of brachytherapy ... applications, today announced that a Life Sciences Discovery ... awarded for which AMIC is the commercialization partner.  ... (WSU) for the proposal titled "Optimized Injectable Radiogels ...
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... NEWARK, N.J., April 6, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... that the New York Stock Exchange (the "NYSE") has notified ... rules due to the Company,s failure to timely file its ... Commission. Under NYSE rules, when a Company ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... of modafinil tablets, a generic version of Teva,s Provigil® ... the Provigil® product.  Par acquired the U.S. marketing rights ... of Cephalon in 2011.  According to IMS Health data, ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2Par Pharmaceutical Begins Shipment of Generic Provigil® 2
(Date:12/21/2014)... December 21, 2014 As testosterone ... heart attacks, stroke and blood clots from using testosterone ... a new study shows that the male hormone testosterone ... In a study published in the Proceedings of the ... Amos-Landgraf examined a group of male rats with naturally ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted ... Whittier offices. The Hope for the Holidays Toy Drive is ... their families during the holiday season. This year, the toy ... between both offices. This event continues to be successful year ... team, store managers and assistant managers came out and not ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering many kinds ... shown its new engineered bamboo flooring collection, and announced ... , BambooIndustry.com’s customers come from many countries in the ... the CEO of the company, the global bamboo flooring ... few years, and the demand for eco-friendly bamboo flooring ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 MissyDress, a ... for all prom lovers. The business has drastically cut ... prom dresses to everyone until Jan. 30, 2015. Many ... dresses, sweetheart dresses, V-neck dresses, lace dresses, and more. ... are not there every day. Whether A-line princess prom ...
(Date:12/20/2014)... December 20, 2014 An improving macroeconomic ... have benefited the Massage Services industry over ... of industry products, the anticipated 1.0% annualized increase in ... provided consumers with the means to afford additional massages. ... a massage in a given year has declined from ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... did language evolve? While the answer might seem obvious ... and other students of communication have debated this question for ... that language is, in fact, poorly designed for communication. Such ... system that probably evolved for other reasons perhaps for ...
... earlier generations, and even the best perform less well. Researchers ... major long-term health impact. The conclusions about the physical ... schoolchildren,s performance in the 3 000-metre race from 1969 to ... Dyrstad at the University of Stavanger (UiS) have drawn on ...
... House effort to ensure that America,s military heroes receive care ... David Geffen School of Medicine at UCLA have pledged to ... care to help train physicians to meet the special needs ... Joining Forces, an initiative launched by first lady Michelle ...
... of two studies suggest that a new, investigational colorectal ... Mayo Clinic and Exact Sciences Inc. of Madison, Wis., ... noninvasive tests at detecting precancerous tumors (adenomas) and early-stage ... tens of thousands of Americans. Early detection is a ...
... made illegal in the UK in 2010, the street price of ... turn may have reduced use of the drug. New research ... mephedrone after it became illegal would switch to a new legal ... or on the Internet. They would be less deterred by ...
... electronic health records (EHRs) are rapidly becoming part of ... providers of care. In the first large study of ... of Nursing determined that nurses working with EHRs consistently ... outcomes for patients than nurses working in hospitals without ...
Cached Medicine News:Health News:MIT: The advantage of ambiguity in language 2Health News:MIT: The advantage of ambiguity in language 3Health News:Sitting it out 2Health News:Sitting it out 3Health News:UCLA joins forces with White House to meet unique needs of veterans, families 2Health News:UCLA joins forces with White House to meet unique needs of veterans, families 3Health News:UCLA joins forces with White House to meet unique needs of veterans, families 4Health News:New test offers greater accuracy in early detection of colorectal cancer 2Health News:New test offers greater accuracy in early detection of colorectal cancer 3Health News:Despite the risks, mephedrone users in the UK are ready to try the next legal high 2Health News:Better together - The RN and the EHR 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: